Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects

Radiolabeled monoclonal antibodies (mAb) have demonstrated measurable antitumor effects in hematologic malignancies. This outcome has been more difficult to achieve for solid tumors due, for the most part, to difficulties in delivering sufficient quantities of mAb to the tumor mass. Previous studies...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer Immunology, Immunotherapy Immunotherapy, 2008-08, Vol.57 (8), p.1173-1183
Hauptverfasser:	Chakraborty, Mala, Gelbard, Alexander, Carrasquillo, Jorge A., Yu, Sarah, Mamede, Marcelo, Paik, Chang H., Camphausen, Kevin, Schlom, Jeffrey, Hodge, James W.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Monoclonal - pharmacokinetics Antibodies, Monoclonal - therapeutic use Antigens Antigens, Neoplasm - immunology Antineoplastic agents Antitumor activity Biological and medical sciences Cancer Research Cancer vaccines Cancer Vaccines - pharmacokinetics Cancer Vaccines - therapeutic use Carcinoembryonic antigen CD4 antigen CD8 antigen Cell Line, Tumor Cells Clinical trials Drug dosages fas Receptor - immunology FasL protein Genotype & phenotype Hematologic Neoplasms - radiotherapy Immunology Immunotherapy Lymphocytes T Medical research Medical sciences Medicine Medicine & Public Health Mice Mice, Transgenic Monoclonal antibodies Oncology Original Original Article Pharmacology. Drug treatments Phenotypes Radiation Radiation therapy Radioimmunotherapy - methods Sensitivity and Specificity Sodium Solid tumors Statistical analysis Tissue Distribution Transgenic mice Treatment Outcome Tumor cells Tumor-infiltrating lymphocytes Tumors Up-Regulation - immunology Vaccines Yttrium Yttrium Radioisotopes - pharmacokinetics Yttrium Radioisotopes - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!